JNJ
The long game is on
Johnson & Johnson is waving the flag for a pretty ambitious future: double-digit growth by 2030. That’s the kind of target that tells investors management isn’t just trying to survive the next quarter — it wants a whole new storyline.
Stelara is the buzzkill
Of course, there’s a catch. Stelara, one of J&J’s big moneymakers, is dragging as competition heats up and the patent clock keeps ticking. So the company is basically saying: yes, the old cash engine is cooling, but the replacement parts are good enough to keep the growth machine humming.
Why you should care
For J&J shareholders, this is the classic “don’t judge us by the patient in the hospital gown” moment. The market tends to care less about promises and more about whether the newer drugs and medtech businesses can actually offset the Stelara slide.
If J&J can pull this off, it’s not just a nice PowerPoint dream — it’s a case for multiple expansion, steadier earnings, and maybe a little less investor eye-rolling.
Big picture: J&J is trying to convince Wall Street it’s not a legacy giant slowly fading into the wallpaper. It wants to be a growth story again, just with more suits and fewer startup hoodies.